Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry
Main findingResult — go to the resultHazard ratio 3.25 95% CI 2.38–4.42Authors' conclusion
In the secondary prevention after percutaneous coronary intervention, platelet reactivity and clinical risk had additive value in predicting outcomes. Platelet reactivity had greater relative impact within 1 month while clinical risk had greater relative impact beyond 1 month.
Study context
- Population
- Patients with CAD who underwent percutaneous coronary intervention (PCI) with drug-eluting stents and had a platelet reactivity unit (PRU) value (PTRG-DES registry)
- Participants
- 11,714 patients
- Exposure
- Combinations of clinical risk and platelet reactivity
- Outcome
- Composite of:
- Cardiac death
- MI
- Stent thrombosis
- Follow-up
- Long-term
Methodological detailslandmark analysis
- Landmark analysis
Main finding
As reported in the abstract
Hazard ratio
3.25
95% CI 2.38–4.42
P < 0.001
By group
High clinical risk/HPRvs Low clinical risk/non-HPR
HR 3.25 (95% CI 2.38–4.42); P < 0.001
- Primary outcome in total population
- 335 (5.3%)
- Difference across the four groups
- P < 0.001
Observational data: associations, not effects.
Further findings
Independent predictors of the primary outcome
- Both PRU and TRS2P were independent predictors of the primary outcome
Landmark analyses · 1 month after PCI
- Risk within 1 month mainly determined by PRU; beyond 1 month mainly by TRS2P
Baseline PRU and TRS2P (total population)
- Mean PRU
- 217.8±78.7
- Mean TRS2P
- 1.56±1.12
Original publication
Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry. Circ Cardiovasc Interv. Published 22 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →